Avience Biomedicals IPO
Avience Biomedicals is an NSE SME IPO listed on the NSE SME platform, priced at ₹196–₹208 per share. The stock debuted at ₹395.2, delivering a listing gain of 90.0%. The IPO had a lot size of ₹600 shares and a minimum investment of ₹2,49,600.
Avience Biomedicals Limited IPO
- IPO Dates
- Jun 18, 2026 – Jun 22, 2026
- Price band
- ₹196-208 per equity share
- Minimum Investment
- ₹2,49,600
- Issue size
- ₹30.24 Cr
- Lot size
- 600
- Allotment Date
- Jun 23, 2026
- Listing
- Jun 25, 2026
- Listing At
- NSE SME
IPO timeline
-
Jun 18, 2026
Open Date
Completed
-
Jun 22, 2026
Close Date
Completed
-
Jun 23, 2026
Allotment Date
Completed
-
Jun 25, 2026
Listing Date
Completed
Unofficial pre-listing indicator
Avience Biomedicals IPO Final GMP Before Listing: ₹100
Avience Biomedicals IPO's final recorded GMP before listing was ₹100 per share (a 48% premium over the ₹208 upper price band). The shares listed at ₹395.2. GMP is unofficial and does not forecast or guarantee the actual listing price.
- Final GMP
- ₹100
- GMP percentage
- 48%
- Upper price band
- ₹208
- Listing price
- ₹395.2
During the recorded period, Avience Biomedicals IPO GMP ranged from ₹25 to ₹100.
Avience Biomedicals IPO GMP trend (day-wise) 14 observations
| Date & time | GMP | Change | GMP % | Indicative price |
|---|---|---|---|---|
| ₹100 | +₹15 | 48% | ₹308 | |
| ₹85 | +₹12 | 41% | ₹293 | |
| ₹73 | +₹9 | 35% | ₹281 | |
| ₹64 | +₹2 | 31% | ₹272 | |
| ₹62 | +₹4 | 30% | ₹270 | |
| ₹58 | −₹2 | 28% | ₹266 | |
| ₹60 | −₹8 | 29% | ₹268 | |
| ₹68 | +₹4 | 33% | ₹276 | |
| ₹64 | +₹6 | 31% | ₹272 | |
| ₹58 | +₹8 | 28% | ₹266 |
Avience Biomedicals IPO Subscription Details
View Subscription DetailsAvience Biomedicals IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.
Last updated:Avience Biomedicals IPO Essentials
Avience Biomedicals IPO Details
Avience Biomedicals IPO is priced at ₹196-208 per share with a total issue size of 30.24 crore. The IPO has a lot size of 600 shares and is listed on NSE SME.
- Issue price
- ₹196-208 per equity share
- Lot size
- 600 shares
- Face value
- ₹10 Per Equity Share
- Issue size
- 14,53,800 shares(agg. up to ₹30.24 Cr)
- Total issue size
- 14,53,800 shares
(aggregating up to ₹30.24 crore) - Fresh issue
- 14,53,800 shares
(aggregating up to ₹30.24 crore) - Listing at
- NSE SME
- List price
- 395.2
- Listing date
- Registrar
- Skyline Financial Services Pvt.Ltd.
- Lead manager
-
Fintellectual Corporate Advisors Pvt.Ltd.
Market Lot Size
Investors can bid for a minimum of 1,200 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual (min) | 2 | 1,200 | ₹2,49,600 |
| Individual(max) | 2 | 1,200 | ₹2,49,600 |
| sHNI(min) | 3 | 1,800 | ₹3,74,400 |
| sHNI(max) | 8 | 4,800 | ₹9,98,400 |
| bHNI(min) | 9 | 5,400 | ₹11,23,200 |
Avience Biomedicals IPO Reservation
Avience Biomedicals IPO reservation details show category-wise allocation of shares. Out of the total 1453800 shares, approximately 18.82% are reserved for QIB, 14.24% for NII, 33.1% for retail investors, 5.65% for market maker, and 28.19% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 409800 (28.19%) | |
| Market Maker Shares Offered | 82200 (5.65%) | |
| QIB Shares Offered | 273600 (18.82%) | |
| NII (HNI) Shares Offered | 207000 (14.24%) | |
| bHNI > ₹10L | 138000 (9.39%) | 77 |
| sHNI < ₹10L | 69000 (4.85%) | 38 |
| Individual Shares Offered | 481200 (33.1%) | 401 |
| Total Shares Offered | 1453800 (100%) |
Avience Biomedicals IPO Analytics
Avience Biomedicals IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Avience Biomedicals IPO Subscription Status
Avience Biomedicals IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO is currently subscribed 385.33x, indicating strong demand across investor categories.
| As on | QIB |
NII
bHNI
sHNI
|
Individual | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 2,73,600 |
2,07,000
1,38,000
69,000
|
4,81,200 | 9,61,800 |
|
Day 1
18-06-26 05:00 PM
|
0.00 x |
13.48x
13.66x
13.10x
|
15.36 x | 10.59 x |
|
Day 2
19-06-26 05:00 PM
|
0.03 x |
66.67x
66.67x
66.67x
|
58.50 x | 43.62 x |
|
Day 3
22-06-26 05:00 PM
|
196.77 x |
597.62x
670.77x
451.32x
|
401.21 x | 385.33 x |
|
Total No. of Applications
|
bHNI | sHNI | Individual |
|---|---|---|---|
| 1,92,895 (Approx) | 214.18x | 403.76x | 401.22x |
Avience Biomedicals Valuations
Earnings
- EPS Pre IPO
- ₹17.94/-
- EPS Post IPO
- ₹12.56/-
- P/E Pre IPO
- 11.59
- P/E Post IPO
- 16.56
Returns
- ROE
- 22.38%
- ROCE
- 16.99%
- RoNW
- 22.38%
Fundamentals
- Debt / Equity
- 0.94
- Price / Book
- 2.94
- Market Cap
- ₹114.09 Cr.
Avience Biomedicals Financials( In Crs.)
| 31-Jan-26 | 31-Mar-25 | 31-Mar-24 | |
|---|---|---|---|
| Assets | 51.96 | 43.60 | 25.63 |
| Revenue | 28.85 | 29.54 | 16.64 |
| Profit After Tax | 4.18 | 5.14 | 1.98 |
| Net Worth | 24.70 | 20.52 | 6.05 |
| Reserves & Surplus | 20.67 | 16.49 | 2.77 |
| Total Borrowing | 17.17 | 13.75 | 7.73 |
Avience Biomedicals Company & Offer Insights
About Avience Biomedicals
Incorporatedin June 2024, Avience Biomedicals Limited is an ISO-certified company involved in the manufacture, supply, and export of molecular diagnostics solutions, with an emphasis on biotechnology, genomics, and the IVD sector.
Avience Biomedicals Limited has diversified its portfolio of products from IVD rapid test kits to include an extensive range of medical devices such as serology products and biochemistry analyzers. It is committed to addressing varied healthcare needs with a special focus only on the B2B and B2G markets.The products of the company are targeted at Pathology Labs, Microbiology Labs, Hospitals, and Research Centers both in the nation and abroad.
Besides being a manufacturer, the Company also acts as a distributor and trader of medical equipment.The company's manufacturing plant is located in Noida, Uttar Pradesh.
As of January 31, 2026, the company has 75 permanent employees and 33 contractual employees.
Avience Biomedicals Promoter(s)
Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal, Ms. Deepa Choudhary are the company's promoters of Avience Biomedicals.
Avience Biomedicals IPO Issue Objectives
- •
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
- •
- Funding the working capital requirements of the Company
- •
- General corporate purposes
Avience Biomedicals IPO - Anchor Investors
Avience Biomedicals Limited finalised its anchor investor allocation on June 17, 2026, raising ₹8.52 crore from 4 institutional investors at an anchor price of ₹208 per share. The anchor book comprises 4,09,800 equity shares allocated across non-mutual fund institutional investors. Sanshi Fund-I received the largest allocation at 35.29%, followed by Meru Investment Fund PCC – Cell 1 at 29.43% and Fortune Hands Growth Fund Scheme I at 23.43%. Shine Star Build Cap Pvt Ltd received the remaining 11.86% of the anchor portion
Contact Information
Contact Details
Avience Biomedicals
1800-12-04-636
C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi - 110058.
Registrar Contact Details
Skyline Financial Services Private Ltd
02228511022
Frequently Asked Questions
Click any question to reveal the answer
Avience Biomedicals IPO is a book-built IPO worth ₹30.24 crore. The price band is ₹196–₹208 per share. The IPO opens on Jun 18, 2026 and closes on Jun 22, 2026. It will be listed on NSE SME Platform. Skyline Financial Services Pvt. Ltd. is the registrar.
The price band of Avience Biomedicals IPO is ₹196 to ₹208 per share.
The lot size of Avience Biomedicals IPO is 600 shares.
The minimum investment for Avience Biomedicals IPO is approximately ₹2,49,600 based on the upper price band .
Avience Biomedicals IPO opens on Jun 18, 2026 and closes on Jun 22, 2026.
The allotment date of Avience Biomedicals IPO is Jun 23, 2026.
Avience Biomedicals IPO is expected to be listed on Jun 25, 2026, on NSE SME Platform.
Avience Biomedicals IPO's final recorded GMP before listing was ₹100 per share (a 48% premium over the ₹208 upper price band). The shares listed at ₹395.2. GMP is unofficial and does not forecast or guarantee the actual listing price.
Avience Biomedicals IPO valuation snapshot: P/E 16.56, EPS ₹12.56/-, P/B 2.94, RoNW 22.38%, and market cap ₹114.09 Cr.
To apply for Avience Biomedicals IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Avience Biomedicals IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Avience Biomedicals IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Avience Biomedicals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Avience Biomedicals IPO allotment status on IPO Ji for quick and easy access.